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adherence, some factors associated with better diabetes control
were identiﬁed.
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OBJECTIVE: The objective of this study is to determine the
direct medical costs associated with patients who have diabetic
retinopathy and their co-morbidities in the state of Florida.
METHODS: The study was a non-randomized, secondary data
analysis using the Florida Ambulatory Patient Data from 2001.
It was a cross-sectional analysis using the individual patient as
the unit of analysis. The ICD-9 Code 362.02 was used to extract
patients with a principle diagnosis of proliferative diabetic
retinopathy (PDR). The ICD-9 Codes 362.01 and 362.10 were
used to extract patients with a principle diagnosis of nonprolif-
erative diabetic retinopathy (NDR). ICD-9 Code 362.83 was
used to extract patients with macular edema (ME). Patient char-
acteristics along with total charges were extracted for each of
these patients. RESULTS: The total charges for Asian, African
American, and White Hispanic are signiﬁcantly lower than the
total charges for Caucasians. However, Black Hispanics have a
statistically signiﬁcant higher total charge than Caucasians.
Patients with Medicare, Medicare HMO, Medicaid, commercial
HMO, and commercial PPO, have statistically signiﬁcant higher
total charges than patients with commercial insurance. Both
PDR and BDR are associated with statistically signiﬁcant greater
total charges than patients with NDR. Yet, the total charges for
ME are signiﬁcantly lower than those for NDR. This model 
is statistically signiﬁcant. CONCLUSIONS: Total charges are
affected by patient characteristics and severity of diabetic
retinopathy. In the state of Florida for 2001, $3,885,952 were
spent on treating patients with diabetic retinopathy and their 
co-morbidities in the ambulatory setting.
PDB11
EVALUATION OF THE CLINICAL OUTCOME AND FINANCIAL
COSTS OF DELAYING THE ONSET OF FRANK 
TYPE-2 DIABETES
McEwan P1, Peters JR2, Currie CJ1
1Cardiff University, Cardiff, UK; 2University Hospital of Wales, Cardiff,
UK
OBJECTIVE: Type-2 diabetes (T2DM) is associated with
increased morbidity and mortality; however, the onset can be
delayed. This study quantiﬁed the impact of delaying the onset
of frank diabetes on the rate of progression to vascular compli-
cations and all associated costs. METHODS: The Cardiff Dia-
betes Simulation Model was run over a 20-year time horizon
following a cohort of 1000 newly diagnosed T2DM patients
compared to a cohort whose T2DM was delayed by two or ten
years. The model utilised the Framingham equations to predict
cardiovascular events before diabetes and the UKPDS equations
following diagnosis. The transition of predicted risk from 
Framingham to the UKPDS risk level was modelled assuming 
an instantaneous switch (Scenario 1) or a linear-progression
between risk equations (Scenario 2). Direct health care costs
[2004, GBP] and outcomes were each discounted at 3.5%.
RESULTS: Assuming no delay in diabetes, the model predicted
501 myocardial infarctions (MI’s), 252 strokes and 2505
microvascular events. Mean costs and quality adjusted life years
(QALY’s) per subject were £11,972 and 7.3 years, respectively.
Mean costs savings ranged from -£2376 to -£4791 (Scenario 1)
and -£123 to -£573 (Scenario 2) through delaying diabetes by
two and ten years, respectively. Mean change in QALY’s ranged
from 0.6 to 1.7 years (Scenario 1) and 0.1 to 1.2 (Scenario 2),
respectively. The number of MI’s avoided ranged from 40 to 224;
while the predicted number of strokes avoided ranged from 37
to 147 for a two-year and ten-year delay, respectively. CON-
CLUSIONS: This study demonstrated that even modest delays
in the onset of diabetes can have a substantial impact on pre-
dicted vascular events and ﬁnancial costs. However, the magni-
tude of this impact was highly dependent upon the modelling
assumption employed relating to the change in cardiovascular
risk as people progress to frank T2DM.
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OBJECTIVE: Glycosylated hemoglobin (HbA1c) is a well-
established measure of glycemic control. Understanding the
impact of staying at target HbA1c levels (£7.0%) on treatment
costs would be of great signiﬁcance to managed care organiza-
tions. The goal of this study was to determine whether being at
target HbA1c results in reductions in diabetes-related costs.
METHODS: This study was a retrospective database analysis
using eligibility, medical and pharmacy claims data, and labora-
tory data from a large US health care organization. Subjects were
included in the study if they had two or more claims for type-2
diabetes and at least one HbA1c value during the period January
1, 2002 through December 31, 2002 (ﬁrst such date identiﬁed
as index date). Subjects with two or more claims for type-1 dia-
betes were excluded from the study. Study subjects were divided
into those at target HbA1c (£7.0%) and above target HbA1c
(>7.0%) and were followed for a period of one year following
their index date. Demographic, clinical and cost variables were
extracted for each subject. Multiple linear regression analysis
was used to compare treatment costs between subjects at target
level and subjects above target level. RESULTS: A total of 3121
subjects were identiﬁed as being continuously at target level and
3659 subjects were identiﬁed as being continuously above target
level. The target group was associated with 30% lower total 
diabetes costs (p < 0.01) after controlling for the confounding
factors (age, gender, health plan region and presence of co-
morbid conditions). The predicted total diabetes costs in the
target group was $1171 and the predicted costs in the above
target group was $1540. CONCLUSION: Results of this analy-
sis suggests that staying at target HbA1c level was associated with
cost savings over a one-year follow-up period in a managed care
setting.
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OBJECTIVES: To collect cost data on the complications of 
diabetes from published sources in France, Germany, Spain and
Italy for use in a peer-reviewed, validated diabetes model.
METHODS: A search for published cost of diabetes complica-
tions data was performed in peer-reviewed journals listed in
PubMed and ISPOR conference proceedings from the last ten
years. Where country-speciﬁc data were not available, we
referred to government websites and local cost experts. Identi-
ﬁed costs were inﬂated to 2004 Euros (€). Major complication
